Literature DB >> 15858858

Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).

Karthik Ramani1, Vivek S Purohit, Razvan D Miclea, C Russell Middaugh, Sathyamangalam V Balasubramanian.   

Abstract

Factor VIII (FVIII) is a multi-domain protein that is important in the clotting cascade. Its deficiency causes Hemophilia A, a bleeding disorder. The unfolding of protein domains can lead to physical instability such as aggregation, and hinder their use in replacement therapy. It has been shown that the aggregation of rFVIIII is initiated by small fluctuations in the protein's tertiary structure (Grillo et al., 2001, Biochemistry 40:586-595). We have investigated the domain(s) involved in the initiation of aggregation using circular dichroism (CD), size exclusion chromatography (SEC), fluorescence anisotropy, domain specific antibody binding, and clotting activity studies. The studies indicated that aggregation may be initiated as a result of conformational change in the C2 domain encompassing the lipid-binding region (2303-2332). The presence of O-phospho-L-Serine (OPLS), which binds to the lipid-binding region of FVIII, prevented aggregation of the protein. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858858      PMCID: PMC2583467          DOI: 10.1002/jps.20340

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

Review 1.  Stability of protein pharmaceuticals.

Authors:  M C Manning; K Patel; R T Borchardt
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

2.  Kinetic study on the irreversible thermal denaturation of yeast phosphoglycerate kinase.

Authors:  M L Galisteo; P L Mateo; J M Sanchez-Ruiz
Journal:  Biochemistry       Date:  1991-02-26       Impact factor: 3.162

3.  Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.

Authors:  P A Foster; C A Fulcher; R A Houghten; T S Zimmerman
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

4.  The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

Authors:  E L Saenko; D Scandella
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

Review 5.  Factor VIII structure and function.

Authors:  P J Fay
Journal:  Thromb Haemost       Date:  1993-07-01       Impact factor: 5.249

6.  Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice.

Authors:  A Braun; L Kwee; M A Labow; J Alsenz
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

7.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.

Authors:  D Scandella; G E Gilbert; M Shima; H Nakai; C Eagleson; M Felch; R Prescott; K J Rajalakshmi; L W Hoyer; E Saenko
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

8.  Formulation design of acidic fibroblast growth factor.

Authors:  P K Tsai; D B Volkin; J M Dabora; K C Thompson; M W Bruner; J O Gress; B Matuszewska; M Keogan; J V Bondi; C R Middaugh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 9.  The molecular pathology of haemophilia.

Authors:  A J Larner
Journal:  Q J Med       Date:  1987-06

10.  Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine.

Authors:  G E Gilbert; D Drinkwater
Journal:  Biochemistry       Date:  1993-09-21       Impact factor: 3.162

View more
  13 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

2.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

3.  Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Authors:  Puneet Gaitonde; Aaron Peng; Robert M Straubinger; Richard B Bankert; Sathy V Balu-Iyer
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

4.  Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.

Authors:  Dipak S Pisal; Matthew P Kosloski; C Russell Middaugh; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2012-03-02       Impact factor: 3.534

5.  Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.

Authors:  Puneet Gaitonde; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  Eur J Pharm Sci       Date:  2014-10-20       Impact factor: 4.384

6.  Aggregation kinetics of recombinant human FVIII (rFVIII).

Authors:  Karthik Ramani; Vivek Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2005-09       Impact factor: 3.534

7.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

8.  Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.

Authors:  Karthik Ramani; Razvan D Miclea; Vivek S Purohit; Donald E Mager; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-04       Impact factor: 3.534

9.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

Review 10.  Delivery of therapeutic proteins.

Authors:  Dipak S Pisal; Matthew P Kosloski; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2010-06       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.